QUEST DIAGNOSTICS INC

Quest Diagnostics CEO’s June 1 insider sale: 10k shares at $194, showing a routine 10b5‑1 plan, minimal impact, and steady company fundamentals.

Quest Diagnostics CFO’s fresh insider buy signals confidence amid earnings growth—investors should watch for more stake‑increases.

Insight into Quest Diagnostics insider sales: why EVP Catherine Doherty’s modest March 2026 sell‑off reflects tax planning, not a warning, and what it signals for shareholders.

Explore how Quest Diagnostics’ executive Patrick Plewman’s RSU grants and tax‑efficient sales reveal insider confidence and liquidity strategy in the health‑care diagnostics market.

Insightful insider trades show Quest Diagnostics’ executives trust its growth—learn how Patrick Plewman’s disciplined buys and sells signal potential upside for investors.